New hope for Tough-to-Treat blood cancer: trial tests adding a pill to standard therapy
NCT ID NCT07385989
Summary
This study is testing if adding a new oral drug, golidocitinib, to a standard chemotherapy and immunotherapy combination works better for people with newly diagnosed, advanced NK/T-cell lymphoma. It will compare the new three-drug combination against the standard two-drug combination in 40 participants. The main goal is to see if more people achieve a complete disappearance of their cancer after the initial treatment phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.